|
2017 Review Paper on RVX-208
|
1
|
Resverlogix Corp.
|
May 10, 2017 03:14PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
2
|
Resverlogix Corp.
|
May 10, 2017 04:00PM
|
|
BETonMACE Hits 18 month Mark
|
5
|
Resverlogix Corp.
|
May 10, 2017 07:54PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
8
|
Resverlogix Corp.
|
May 11, 2017 10:19AM
|
|
Re: A couple Q2 events for Zenith
|
4
|
Zenith Epigenetics
|
May 11, 2017 10:58AM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
5
|
Resverlogix Corp.
|
May 11, 2017 12:32PM
|
|
Is Bioasis attending this BBB conference?
|
|
BIOASIS TECHNOLOGIES INC
|
May 11, 2017 12:55PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
4
|
Resverlogix Corp.
|
May 12, 2017 11:14AM
|
|
Re: Futilitcy analysis
|
3
|
Resverlogix Corp.
|
May 12, 2017 11:23AM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
1
|
Resverlogix Corp.
|
May 12, 2017 11:48AM
|
|
Same story, different conference
|
2
|
Resverlogix Corp.
|
May 13, 2017 12:21PM
|
|
Re: Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
|
6
|
Resverlogix Corp.
|
May 15, 2017 10:37AM
|
|
Re: Pfizer enzalutimide perspective
|
7
|
Zenith Epigenetics
|
May 16, 2017 10:49AM
|
|
Resverlogix tweet regarding apabetalone/CKD
|
7
|
Resverlogix Corp.
|
May 16, 2017 10:49PM
|
|
Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?
|
5
|
Resverlogix Corp.
|
May 17, 2017 11:55AM
|
|
Re: Resverlogix tweet regarding apabetalone/CKD
|
5
|
Resverlogix Corp.
|
May 17, 2017 11:57AM
|
|
Re: Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?
|
4
|
Resverlogix Corp.
|
May 17, 2017 12:29PM
|
|
Re: Evacetrapib fails
|
4
|
Resverlogix Corp.
|
May 18, 2017 08:49AM
|
|
Re: Evacetrapib fails
|
4
|
Resverlogix Corp.
|
May 18, 2017 11:02AM
|
|
BETting on a new heart failure treatment
|
2
|
Resverlogix Corp.
|
May 18, 2017 11:31AM
|
